Semaglutide vs Cagrilintide: Next-Gen Weight Loss Peptides

Semaglutide mimics GLP-1, a gut hormone that signals satiety to the brain, slows gastric emptying, and enhances insulin secretion. At the 2.4mg weekly dose (Wegovy), it produces average weight loss of 15-17% in clinical trials.

Beyond weight loss, semaglutide has demonstrated cardiovascular benefits (SELECT trial), reduced kidney disease progression, and potential neuroprotective effects. It has become the gold standard in GLP-1 therapy.

Cagrilintide is a long-acting analog of amylin, a hormone co-secreted with insulin by pancreatic beta cells. Amylin promotes satiety through the area postrema in the brainstem, slows gastric emptying, and suppresses glucagon secretion.

Critically, amylin signaling is a distinct pathway from GLP-1, which is why combining the two produces additive weight loss effects. Cagrilintide alone produced ~10-11% weight loss in phase 2 trials.

Novo Nordisk's CagriSema combines semaglutide + cagrilintide in a single weekly injection. Phase 3 data showed ~22-25% body weight reduction — approaching what was previously only achievable with bariatric surgery.

The dual-mechanism approach targets two independent satiety pathways, reducing appetite more comprehensively than either drug alone. CagriSema is expected to receive FDA approval and could redefine obesity treatment standards.

As standalone therapies, semaglutide is more effective for weight loss (~15-17% vs ~10-11%). However, the real story is the combination — CagriSema outperforms both. For researchers studying these peptides individually, semaglutide has a more established evidence base and wider availability.

Ascension Peptides offers research-grade semaglutide with full third-party testing. As cagrilintide moves through clinical trials, availability for research purposes is expanding. Always verify certificates of analysis and purity standards.